Date: 2013-04-04
Type of information: Services contract
Compound: combined test and medical informatics solution
Company: OncoDNA (Belgium) CollabRx (USA)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
services
Action mechanism:
Disease:
Details: CollabRx, a data analytics company focused on informing clinical decision making in molecular medicine, and OncoDNA, a Belgium company that provides DNA next generation sequencing (NGS) tests for clinical use in cancer, have announced a multi-year agreement to purchase CollabRx SaaS-based technology and content resources to be used in conjunction with OncoDNA’s cancer mutation panels.
OncoDNA and CollabRx will develop a combined test and medical informatics solution by pairing the results of cancer mutational panels developed by OncoDNA with clinically actionable and dynamically updated knowledge provided by CollabRx. Such knowledge includes the clinical impact of specific mutational profiles and associated therapeutic strategies such as drugs and clinical trials and is supported by CollabRx’s large and growing network of over 75 leading clinical practitioners in the U.S. and Europe. The partnership, CollabRx’s first outside the United States, will leverage the company’s semantic integration platform, a proprietary technology that enables CollabRx scientists and physicians to dynamically update the company’s molecular oncology knowledge base with the latest medical and scientific data available in the public domain.
Financial terms:
Latest news:
